<p>Doxorubicin is an anthracycline topoisomerase II inhibitor indicated for:</p>

<ul>
	<li><strong>Ovarian cancer</strong>: After failure of platinum-based chemotherapy.</li>
	<li><strong>AIDS-related Kaposi&rsquo;s Sarcoma</strong>: After failure of prior systemic chemotherapy or intolerance to such therapy.</li>
	<li><strong>Multiple Myeloma</strong>: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.</li>
</ul>